Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
165 studies found for:    Neurofibromatosis
Show Display Options
Rank Status Study
1 Unknown  Modifying Genes in Neurofibromatosis 1
Condition: Neurofibromatosis 1
Intervention: Other: No intervention
2 Completed Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)
Condition: Neurofibromatosis Type 1
Intervention:
3 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
4 Recruiting Neurofibromatosis Type 1 Patient Registry
Condition: Neurofibromatosis Type 1
Intervention:
5 Unknown  Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Conditions: Whole Body Imaging;   Magnetic Resonance Imaging;   Neurofibromatosis 1;   Diffusion Magnetic Resonance Imaging;   Peripheral Nerve Sheath Tumors, Malignant
Intervention: Other: Additional imaging or surgery
6 Active, not recruiting Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
Conditions: Neurofibromatosis 1;   Cutaneous Neurofibroma
Interventions: Drug: Diclofenac Sodium;   Drug: Saline Solution
7 Completed Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
8 Completed
Has Results
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Condition: Neurofibromatosis Type 1
Intervention: Drug: Sirolimus
9 Enrolling by invitation Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
Condition: Neurofibromatosis 1
Intervention: Other: Blood sample
10 Completed Reliability of Functional Outcome Measures in Neurofibromatosis 1
Condition: Neurofibromatosis 1, NF1
Intervention:
11 Completed Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Condition: Neurofibromatosis
Intervention: Drug: Pirfenidone
12 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
13 Completed Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
Condition: Neurofibromatosis Type 1
Intervention: Other: Neuropsychological examination and quality of life measures
14 Completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Conditions: Neurofibromas;   Neurofibromatosis Type 1
Intervention:
15 Completed Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Condition: Neurofibromatosis 1
Intervention: Drug: Everolimus
16 Unknown  Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.
Condition: Neurofibromatosis Type 1
Intervention:
17 Active, not recruiting PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
Conditions: Neurofibromatosis-1;   Optic Glioma;   Plexiform Neurofibroma
Intervention:
18 Completed Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
Condition: Neurofibromatosis 1
Interventions: Drug: Lovastatin;   Drug: placebo pill
19 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
20 Completed
Has Results
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.